Navigation Links
Edwards Lifesciences Announces Schedule of Activities at TCT 2007
Date:10/16/2007

Program Includes Clinical Presentations Featuring Edwards' Interventional

Cardiovascular Technologies, Analyst Luncheon

IRVINE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced its schedule of activities for the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, from Oct. 20 through 25 in Washington, D.C.

Edwards will also host an analyst luncheon on Wednesday, Oct. 24, at 12:00 p.m. EDT. The featured speakers at the luncheon will be Augusto Pichard, M.D., Professor of Medicine and Director of the Cardiac Catheterization Laboratories, Washington Center Hospital, Washington, D.C., and Alex Powell, M.D., Interventional Radiologist, Baptist Cardiac and Vascular Institute, Miami, Fla.

Dr. Pichard will discuss his experiences with the Edwards SAPIEN transcatheter aortic heart valve and the RetroFlex transfemoral delivery system. He will also provide his perspective on the potential this valve replacement technology has in treating high-risk patients suffering from severe aortic stenosis.

Dr. Powell will discuss the one-year results from the RESILIENT trial, the landmark randomized study of the Edwards LifeStent Self-Expanding Stent for the treatment of peripheral vascular disease in the superficial femoral artery (SFA).

A live webcast of the presentation will be available on the Edwards investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm from 12:30 to 1:30 p.m. EDT. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.

In addition to the analyst luncheon, the TCT program will include a number of clinical presentations featuring several of Edwards' interventional cardiovascular technologies. Among the presentations are (all times EDT):

Sunday, Oct. 21

-- The Valvular Heart Disease Summit -- 8:00 a.m. to 7:00 p.m., Room

202B, co-sponsored by Edwards. The summit will cover topics including

mitral regurgitation therapies, transcatheter mitral valve repair and

replacement, transcatheter pulmonic valve replacement, aortic stenosis

and new devices. Presentations during the summit include: an overview

of Edwards' transcatheter heart valve replacement program, an update

on the status of the PARTNER pivotal trial for this device and interim

results from the EVOLUTION feasibility study, which utilizes Edwards'

MONARC system, a device intended to treat functional mitral

regurgitation in heart failure patients.

Monday, Oct. 22

-- Advanced Endovascular Techniques for the Treatment of Infrainguinal

Disease -- 7:00 a.m. to 8:00 a.m., Room 149AB, supported through an

educational grant by Edwards. The breakfast meeting will address

techniques and technologies for the treatment of infrainguinal

disease, as well as adjunct therapies.

Tuesday, Oct. 23

-- "Blockbuster" Trial of the Day: RESILIENT -- 11:00 a.m. to 12:00 p.m.,

Main Arena, Ballrooms ABC, Level 3. Presentations will address the

one-year results from the RESILIENT trial, the landmark randomized

study of the Edwards LifeStent Self-Expanding Stent in the SFA.

-- Hot Topics 2007/2008: Regulatory Pathways for Percutaneous Aortic

Valves -- 2:15 p.m. to 2:45 p.m., Room 207AB. Jodi J. Akin, Edwards

Lifesciences' vice president of clinical affairs, Heart Valve Therapy,

presents the industry perspective in a discussion with representatives

from the U.S. Food and Drug Administration, academia and industry

about clinical studies and regulatory approval for percutaneous

technology. Stanton Rowe, Edwards' corporate vice president, Advanced

Technology, will also serve as one of the discussants.

Wednesday, Oct. 24

-- Transcatheter Heart Valve Fundamentals from Science to Patient:

Edwards SAPIEN Transcatheter Heart Valve -- 7:00 a.m. to 8:00 a.m.,

Room 152A. The breakfast meeting will provide an overview of the

Edwards SAPIEN transcatheter valve's design, development and

performance in patients.

Representatives from Edwards will also be in the exhibition area at booth 5041 on level two.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards, Edwards SAPIEN, MONARC and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Doctors Hopeful for Elizabeth Edwards
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and ... Fitness has delved into this niche allowing those giving up their beloved pasta a ... 30 grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ...
(Date:2/13/2016)... Salt Lake City, Utah (PRWEB) , ... February 13, 2016 , ... When an ... kids, Host Parents aren’t always sure what they are in for and they are often ... Pairs are more than they were hoping for. This year’s Au Pair of the Year ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, ... Parishes. The purpose of these scholarships is to encourage applicants to pursue a ... seek employment within these two parishes. , “We have available jobs in St. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Each year, ... will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical ... see new therapy products in action, learn more about their chosen field and network ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... as a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) ... channel partners to offer real-time business intelligence (BI) to their small and medium ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... the Company will ring the Nasdaq Closing Bell at ... York at 4:00 p.m. ET on Tuesday, ... Adrian Adams , will perform the ... to 4:00 p.m. ET.  A live webcast will be ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
Breaking Medicine Technology: